Dova Pharmaceuticals (NASDAQ:DOVA) had its price target hoisted by equities research analysts at JPMorgan Chase & Co. from $13.00 to $15.00 in a research report issued on Friday, BenzingaRatingsTable reports. The firm presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential downside of 11.71% from the stock’s current price.
Several other analysts have also recently commented on DOVA. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. Evercore ISI raised Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 price target for the company in a report on Monday, July 1st. HC Wainwright raised their price target on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Wedbush set a $190.00 price target on Home Depot and gave the company a “hold” rating in a report on Wednesday, May 22nd. Finally, BidaskClub raised Zillow Group from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $28.56.
DOVA opened at $16.99 on Friday. The company has a quick ratio of 4.27, a current ratio of 4.46 and a debt-to-equity ratio of 0.20. The company has a 50 day simple moving average of $11.35. The firm has a market cap of $472.90 million, a PE ratio of -6.53 and a beta of 2.56. Dova Pharmaceuticals has a 12 month low of $5.62 and a 12 month high of $26.49.
In related news, CEO David Zaccardelli sold 10,450 shares of Dova Pharmaceuticals stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $15.94, for a total transaction of $166,573.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jason Hoitt sold 2,387 shares of Dova Pharmaceuticals stock in a transaction on Friday, June 28th. The stock was sold at an average price of $13.81, for a total value of $32,964.47. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 582,854 shares of company stock valued at $8,243,825 and have sold 18,838 shares valued at $284,611. Insiders own 60.30% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. FMR LLC raised its holdings in Dova Pharmaceuticals by 0.8% during the first quarter. FMR LLC now owns 1,347,521 shares of the company’s stock worth $11,979,000 after purchasing an additional 10,970 shares during the last quarter. Sanders Morris Harris LLC raised its holdings in Dova Pharmaceuticals by 85.1% during the second quarter. Sanders Morris Harris LLC now owns 521,887 shares of the company’s stock worth $7,359,000 after purchasing an additional 239,972 shares during the last quarter. Sphera Funds Management LTD. raised its holdings in Dova Pharmaceuticals by 54.2% during the fourth quarter. Sphera Funds Management LTD. now owns 185,000 shares of the company’s stock worth $1,402,000 after purchasing an additional 65,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Dova Pharmaceuticals by 8.1% in the fourth quarter. Geode Capital Management LLC now owns 156,232 shares of the company’s stock worth $1,184,000 after acquiring an additional 11,732 shares during the last quarter. Finally, Spark Investment Management LLC raised its holdings in shares of Dova Pharmaceuticals by 31.8% in the first quarter. Spark Investment Management LLC now owns 80,500 shares of the company’s stock worth $715,000 after acquiring an additional 19,400 shares during the last quarter. 30.18% of the stock is owned by hedge funds and other institutional investors.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Featured Story: Average Daily Trade Volume – ADTV
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.